StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

1
Player Avatar stemcells2011 (< 20) Submitted: 4/13/2011 11:52:09 AM : Outperform Start Price: $7.85 STEM Score: -91.38

Stem cells

Featured Broker Partners


Advertisement